CONMED (CNMD) Projected to Post Quarterly Earnings on Wednesday

CONMED (NYSE:CNMD - Get Free Report) is anticipated to release its earnings data after the market closes on Wednesday, February 5th. Analysts expect CONMED to post earnings of $1.20 per share and revenue of $341.05 million for the quarter. Persons that are interested in participating in the company's earnings conference call can do so using this link.

CONMED (NYSE:CNMD - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.05 EPS for the quarter, beating analysts' consensus estimates of $0.99 by $0.06. The company had revenue of $316.70 million for the quarter, compared to analyst estimates of $318.46 million. CONMED had a return on equity of 13.84% and a net margin of 10.23%. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Stock Performance

Shares of CNMD traded up $0.98 during trading hours on Friday, reaching $71.84. 452,049 shares of the company's stock traded hands, compared to its average volume of 395,122. The business's fifty day simple moving average is $70.83 and its two-hundred day simple moving average is $70.20. CONMED has a twelve month low of $61.05 and a twelve month high of $97.08. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of 17.06, a P/E/G ratio of 1.02 and a beta of 1.47. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.27 and a quick ratio of 1.06.

CONMED Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 3rd. Investors of record on Friday, December 20th were given a $0.20 dividend. The ex-dividend date of this dividend was Friday, December 20th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.11%. CONMED's dividend payout ratio (DPR) is 19.00%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Needham & Company LLC reiterated a "buy" rating and issued a $97.00 price target on shares of CONMED in a research report on Thursday, October 31st. StockNews.com lowered CONMED from a "buy" rating to a "hold" rating in a research report on Friday, November 8th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $79.80.

About CONMED

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.